All In Biotech

Drug Trial Radar · NCT04987671

Pharmacokinetic and Pharmacodynamic Study of AMX0035 in Patients With ALS

A Pharmacokinetic and Pharmacodynamic Study of AMX0035 in Patients With ALS

Last checked: Nov 19, 2026Latest source record: Jul 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

14

Planned (sponsor's estimate)

Start

Aug 5, 2021

Primary completion

May 11, 2022

Study completion Sep 2023

Sponsor

Lead sponsor
Amylyx Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
Aug 3, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the pharmacokinetic and pharmacodynamic effect after a single dose or at steady state after multiple doses of AMX0035 in adults with sporadic ALS.

Conditions

  • ALS

Interventions

  • AMX0035Drug

    Fixed dose combination of Sodium Phenylbutyrate and taurursodiol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Blood concentration of PB and taurursodiolTime frame: Between Day 1 and Day 40
  2. Systemic exposure to PB and taurursodiolTime frame: Between Day 1 and Day 40

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Norman Fixel Institute for Neurological Diseases

    Gainesville, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.